Product Description
Mechanisms of Action: FAK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Pancreatic Cancer|Meningioma
Phase 1: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Pleural Cancer|Skin Cancer|Goodpasture Syndrome|Mesothelioma|Glioblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02551653 |
NCT02551653 | P1 |
Completed |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2017-03-14 |
2019-03-20 |
||
NCT01938443 |
NCT01938443 | P1 |
Completed |
Mesothelioma|Pleural Cancer |
2016-06-23 |
2019-03-19 |
||
NCT01138033 |
NCT01138033 | P1 |
Completed |
Goodpasture Syndrome|Skin Cancer|Glioblastoma |
2015-12-21 |
2019-03-19 |
Treatments |
|
NCT00996671 |
FTIH | P1 |
Completed |
Skin Cancer |
2010-03-17 |
2019-03-19 |
Treatments |
|
NCT02523014 |
A071401 | P2 |
Recruiting |
Meningioma |
2027-01-01 |
12% |
2026-01-13 |
Primary Completion Date|Primary Endpoints|Start Date |
NCT02428270 |
MOBILITY-002 | P2 |
Completed |
Adenocarcinoma|Pancreatic Cancer |
2017-06-01 |
28% |
2022-11-02 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |